Zurcher Kantonalbank Zurich Cantonalbank Buys 7,244 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 82.7% in the 4th quarter, HoldingsChannel reports. The fund owned 16,006 shares of the company’s stock after buying an additional 7,244 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in GoodRx were worth $107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of GDRX. Dark Forest Capital Management LP purchased a new stake in shares of GoodRx during the third quarter valued at approximately $2,454,000. Gotham Asset Management LLC boosted its position in GoodRx by 121.6% during the 3rd quarter. Gotham Asset Management LLC now owns 72,090 shares of the company’s stock valued at $406,000 after buying an additional 39,552 shares during the period. Citigroup Inc. grew its holdings in GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after acquiring an additional 6,006 shares during the last quarter. Vanguard Group Inc. increased its position in shares of GoodRx by 2.1% in the third quarter. Vanguard Group Inc. now owns 8,681,111 shares of the company’s stock valued at $48,875,000 after acquiring an additional 177,961 shares during the period. Finally, Fuller & Thaler Asset Management Inc. bought a new position in shares of GoodRx during the third quarter valued at about $8,866,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Trading Down 8.9 %

NASDAQ GDRX opened at $6.93 on Friday. The stock’s fifty day moving average price is $7.05 and its 200-day moving average price is $6.38. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.85. The stock has a market cap of $2.74 billion, a P/E ratio of -346.33, a P/E/G ratio of 3.89 and a beta of 1.37. GoodRx Holdings, Inc. has a 12 month low of $4.14 and a 12 month high of $9.37.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $196.64 million during the quarter, compared to analyst estimates of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. As a group, equities analysts forecast that GoodRx Holdings, Inc. will post 0.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on GDRX shares. Royal Bank of Canada boosted their price target on GoodRx from $7.00 to $8.00 and gave the company a “sector perform” rating in a report on Friday, March 1st. KeyCorp raised GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research note on Wednesday, April 10th. UBS Group upped their price objective on shares of GoodRx from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, March 1st. The Goldman Sachs Group lifted their target price on shares of GoodRx from $6.50 to $7.50 and gave the company a “neutral” rating in a research note on Friday, March 1st. Finally, JPMorgan Chase & Co. upgraded shares of GoodRx from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $7.00 to $10.00 in a report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.78.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.